A new gene therapy start-up, Eudora, has been launched by the Anglo-American genome writing company Replay.
Based in London and California, Replay is focused on “writing and delivering big DNA,” and has a distinctive approach to its corporate structure, aiming to separate work on its technology from the resulting therapeutic candidates.
The company has assembled a toolkit of what it hopes will be disruptive platform technologies, including a high payload capacity herpes simplex virus (HSV) platform, a hypoimmunogenic platform, and a genome writing platform.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze